Dimenhydrinate (CAS 523-87-5): A Comprehensive Overview for Pharmaceutical Applications

Dimenhydrinate, a widely recognized active pharmaceutical ingredient (API), stands as a cornerstone in the prevention and treatment of a range of distressing conditions, primarily motion sickness. Its efficacy against nausea, vomiting, and dizziness has solidified its position as an essential compound in the global pharmaceutical market. NINGBO INNO PHARMCHEM CO.,LTD. is proud to present a high-quality Dimenhydrinate API, meticulously produced to meet stringent industry standards.

Chemically, Dimenhydrinate is a unique salt composed of two distinct entities: Diphenhydramine, a potent antihistamine, and 8-chlorotheophylline, a chlorinated derivative of theophylline. This synergistic combination provides its characteristic therapeutic effects. The pharmacological actions of Dimenhydrinate largely stem from its Diphenhydramine component, which exhibits significant central nervous system (CNS) depressant, anticholinergic, antiemetic, and antihistaminic properties. The presence of 8-chlorotheophylline, while often less emphasized, is chemically related to caffeine and contributes to the overall profile, potentially offsetting some of the more pronounced sedative effects of Diphenhydramine, though drowsiness remains a primary characteristic.

The primary utility of Dimenhydrinate lies in its profound antiemetic action, which is believed to result from its ability to inhibit vestibular stimulation. By acting on the balance-sensing organs in the inner ear, particularly the otolith system and, at higher doses, the semicircular canals, it effectively mitigates the conflicting signals that lead to motion sickness. Furthermore, its anticholinergic properties play a crucial role by inhibiting acetylcholine, a neurotransmitter implicated in the vestibular and reticular systems responsible for motion-induced nausea and vomiting. This dual mechanism ensures comprehensive relief from symptoms associated with various forms of motion-induced discomfort, from sea and car sickness to air travel disturbances. Beyond motion sickness, Dimenhydrinate has also been successfully employed for the symptomatic treatment of Meniere's disease and other vestibular disorders, offering relief from associated vertigo and imbalance. Its utility extends to veterinary medicine, where it serves as an effective antiemetic and sedative for housepets, particularly in cases of idiopathic vestibular syndrome.

Dimenhydrinate is available in numerous pharmaceutical formulations, including oral tablets, chewable tablets, oral solutions, and injectable forms, providing versatility in administration. When taken orally, its antiemetic effects typically manifest within 15 to 30 minutes, with the effects lasting for approximately three to six hours. For optimal prevention of motion sickness, it is generally recommended to administer the drug about 30 minutes before exposure to motion.

While generally safe and effective, users should be aware of potential side effects and precautions. The most common adverse effect is drowsiness, which can significantly impair the ability to drive or operate heavy machinery. Other reported side effects include dizziness, blurred vision, dry mouth, nose, or throat, headache, and gastrointestinal disturbances such as constipation or diarrhea. Paradoxical CNS stimulation, leading to restlessness or insomnia, can occur, especially in children. It is crucial to use Dimenhydrinate with caution in patients with pre-existing conditions such as glaucoma, prostate enlargement, seizure disorders, or chronic respiratory conditions like asthma or emphysema, as its anticholinergic properties can exacerbate these conditions. Furthermore, co-administration with other CNS depressants, including alcohol, sedatives, tranquilizers, and certain pain relievers, can lead to enhanced sedation and should be carefully managed. Due to its potential to mask signs of ototoxicity, Dimenhydrinate should be used judiciously in patients receiving ototoxic drugs. It is generally not recommended for use in premature infants or neonates, and nursing mothers should consult a healthcare professional as small amounts may pass into breast milk.

As a leading Dimenhydrinate manufacturer and supplier, NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing pharmaceutical companies worldwide with API of uncompromising purity and quality. Our state-of-the-art production facilities adhere to the highest international pharmaceutical standards, ensuring a reliable and consistent supply. For those looking to buy Dimenhydrinate API or inquire about Dimenhydrinate price, we offer competitive rates and flexible terms, including FOB, EXW, CFR, CIF, DDP, DAP, CIP, CPT, and FCA. We invite prospective clients to purchase Dimenhydrinate from a trusted partner with a proven track record. Customization options are available to meet specific client needs, reinforcing our position as a preferred Dimenhydrinate supplier in the global market. Our robust production capacity of 200 tons per year ensures that we can fulfill orders of varying scales, making us an ideal partner for both large-scale production and niche applications. Contact us today to discuss your Dimenhydrinate requirements and experience the excellence that defines our products and services.